HC Wainwright restated their buy rating on shares of Elevation Oncology (NASDAQ:ELEV – Get Rating) in a report published on Monday morning, Marketbeat.com reports. HC Wainwright currently has a $7.50 price objective on the stock.
ELEV has been the subject of several other research reports. JPMorgan Chase & Co. downgraded shares of Elevation Oncology from an overweight rating to a neutral rating in a report on Monday, August 8th. Wedbush dropped their target price on shares of Elevation Oncology from $15.00 to $8.00 and set an outperform rating for the company in a report on Friday, July 29th. Finally, SVB Leerink reiterated an outperform rating on shares of Elevation Oncology in a report on Wednesday, July 27th.
Elevation Oncology Price Performance
Shares of NASDAQ ELEV opened at $1.03 on Monday. The company has a 50 day simple moving average of $1.24 and a 200-day simple moving average of $2.01. The company has a market capitalization of $23.99 million, a P/E ratio of -0.41 and a beta of 0.82. Elevation Oncology has a 1 year low of $0.98 and a 1 year high of $8.99.
Hedge Funds Weigh In On Elevation Oncology
Institutional investors have recently modified their holdings of the business. Sio Capital Management LLC acquired a new position in shares of Elevation Oncology in the fourth quarter worth $1,505,000. TCG Crossover Management LLC purchased a new stake in Elevation Oncology in the fourth quarter valued at $3,341,000. Marquette Asset Management LLC lifted its position in Elevation Oncology by 332.5% in the first quarter. Marquette Asset Management LLC now owns 38,951 shares of the company’s stock valued at $98,000 after acquiring an additional 29,945 shares during the last quarter. Renaissance Technologies LLC lifted its position in Elevation Oncology by 917.3% in the second quarter. Renaissance Technologies LLC now owns 258,400 shares of the company’s stock valued at $362,000 after acquiring an additional 233,000 shares during the last quarter. Finally, BlackRock Inc. lifted its position in Elevation Oncology by 57.4% in the first quarter. BlackRock Inc. now owns 38,218 shares of the company’s stock valued at $96,000 after acquiring an additional 13,936 shares during the last quarter. Institutional investors and hedge funds own 74.04% of the company’s stock.
Elevation Oncology Company Profile
Elevation Oncology, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion.
- Get a free copy of the StockNews.com research report on Elevation Oncology (ELEV)
- The Institutions Hold On To Darden Restaurants International
- What Steelcase’s Earnings Say About the Return to the Office?
- Is The Golden Age Of Homebuilding Already Over?
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for Elevation Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevation Oncology and related companies with MarketBeat.com's FREE daily email newsletter.